Crossing the Same River Multiple Times

Every year, the editors of Pharmaceutical Technology Europe conduct a survey (1) designed to measure the state of the bio/pharma industry. The editors selected several intriguing areas of opportunities for participants to choose between, and as shown in Figure 8, just under half (47.3%) chose cell and gene therapies. In addition to cell and gene therapies, machine learning and artificial intelligence (22.3%) also drew significant interest from the survey population.

Outsourcing's, Race Toward Novelty

According to Jeetendra Vaghjiani, senior director of clinical development and strategic marketing at Lonza, emerging biotech companies are reliant on contract development and manufacturing organizations (CDMOs) because of their development and manufacturing capacity, expertise, and flexibility. Because of the high attrition rate associated with drug development, the better your preclinical programme, the stronger the position you can establish in terms of programme design and patient identification (2). [...]because of the relative scarcity of approvals over the past decade, companies looking to capitalize on this new market are likely to require specialized knowledge to get through the approvals process.

Advances in Dissolution Testing

With everything from real-time release testing to automated regulatory audit trail software continuing to gain prominence in the sector, an in-depth look toward the future of dissolution testing is needed for those seeking comprehensive understanding of the industry. [...]things like remote instrument monitoring, maintenance, validation, and possibly repair, software as a service, etc. start becoming subjects of discussion. Together with the move to software control discussed previously, this may make these concepts palatable and applicable to pharma the way they are accepted as de facto in many other industries.

Crossing the Same River Multiple Times: Cautiously setting aside pandemic practices, pharma workers appear ready for flux, change, evolution, and expanding molecular diversity

The article presents results of an employment survey on trends and the state of the biotechnology and pharmaceutical industry in 2022. Findings reveal COVID-19 measures that are important to daily operations, stagnation of wage growth and decline in overall salary satisfaction, job security changes and drop in job satisfaction, and business concerns including corporate performance and industry growth.

Crossing the Same River Multiple Times: Cautiously setting aside pandemic practices, pharma workers appear ready for flux, change, evolution, and expanding molecular diversity

The article reports that the survey assesses various employment metrics, thoughts on ongoing trends and predictions for the future of the industry. Topics include examines the intent is to not only create a snapshot of the bio/pharma industry as it exists in 2022, but to also encapsulate the thoughts and feelings of those within.